Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ONXX -- Ignore unavailable to you. Want to Upgrade?

To: Mama Bear who wrote (631)	9/23/2000 1:04:45 PM
From: tom pope	Read Replies (1) \| Respond to of 810

>>Of course a diversified portfolio of development stage biotechs could pay off with above average returns. << Obviously diversifying holdings of small biotechs is key. It would be daft to have more than 1-2% in an ONXX based on the information we have now. I'm not certain what the commotion about insider selling is about. Unless the insider trading data service I subscribe to is hopelessly out of date, insiders sold or filed to sell all of 61,237 shares in August. Since Yahoo reports insiders as holding 42% of the company, that's not exactly "lining up to sell." The institutional selling was admittedly more impressive, bringing their holdings down from 17 to 12% If there is later data, please post. What I have is: insidertrader.com Since it's a subscription site it may not work.